Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2024
Product Development

Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks

Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood  
BioCentury | May 23, 2023
Deals

Sizing up VectivBio’s takeout premium among '23 M&A deals

Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | May 1, 2018
Distillery Therapeutics

Autoimmune disease

BioCentury | Jul 28, 2017
Clinical News

Zealand's glepaglutide meets in Phase II for SBS

BioCentury | Jul 7, 2017
Financial News

Zealand planning NASDAQ listing

BioCentury | Feb 16, 2017
Clinical News

Glepaglutide: Completed Ph II enrollment

BioCentury | May 9, 2016
Clinical News

Elsiglutide: Phase IIb data

BioCentury | May 5, 2016
Clinical News

Helsinn's elsiglutide misses in Phase IIb trial

Items per page:
1 - 10 of 23